Key result
Soluble guanylate cyclase stimulators, particularly vericiguat, reduce hospitalizations in high-risk patients with heart failure with reduced ejection fraction, but lack benefit in preserved ejection fraction.
Why the study?
Despite advances in medical management, heart failure prognosis remains poor, justifying the search for newer therapeutic agents such as soluble guanylate cyclase stimulators.
Do soluble guanylate cyclase stimulators improve clinical outcomes in patients with heart failure?
Do soluble guanylate cyclase stimulators improve clinical outcomes in patients with heart failure?
Soluble guanylate cyclase stimulators, particularly vericiguat, are a promising secondary therapy for reducing hospitalizations in high-risk HFrEF patients, though they lack demonstrated efficacy in HFpEF.
May support vericiguat to reduce HFrEF hospitalizations in high-risk patients; leaves open HFpEF efficacy pending prospective trials.
Heart failure has a high global burden of morbidity and mortality. Despite significant advances in medical management of heart failure, the prognosis remains poor. This justifies the search for newer therapeutic agents. Recently, soluble guanylate stimulators have demonstrated favorable results in clinical trials. This article aims to summarize the guanylate cyclase signaling pathway, the role of soluble guanylate cyclase stimulators in heart failure, and data from recent clinical trials of these drugs. We concluded that soluble guanylate cyclase stimulators have significant benefits in reducing hospitalizations in patients with heart failure with reduced ejection fraction that are at high risk of cardiovascular events. There appears to be no benefit of these drugs in patients with heart failure with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Kansakar et al. (2021) conducted a review in Heart failure. Soluble guanylate cyclase stimulators vs. Placebo was evaluated. Soluble guanylate cyclase stimulators, particularly vericiguat, reduce hospitalizations in high-risk patients with heart failure with reduced ejection fraction, but lack benefit in preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: